AI Article Synopsis

  • This study investigates how Mild Cognitive Impairment (MCI), Mild Behavioral Impairment (MBI), and cognitive complaints (CC) can predict the risk of developing dementia or Alzheimer’s disease in older adults.
  • Participants included 598 older adults without dementia at the start of the study, who were monitored for up to 12 years for any diagnosis of dementia.
  • Results showed that combinations of MCI and CC significantly increased the risk of dementia, with the highest risk linked to those with MCI, CC, and MBI combined, while MBI only or CC only did not increase risk.

Article Abstract

Background: Mild Cognitive Impairment (MCI) and Mild Behavioral Impairment (MBI) represent transitional states between normal aging and incipient dementia. We examined whether presence of cognitive complaint (CC), MCI, and MBI differentially predicted risk for all-cause dementia or Alzheimer's disease (AD) in a population-based sample.

Method: Participants included 598 older adults [55% female, with mean (SD) age = 78.84 (7.51) years] without dementia at baseline of the Cache County Study on Memory in Aging. All completed a clinical assessment and were followed in subsequent waves until dementia diagnosis or non-participation, for a maximum follow-up time of 12 years. MCI classification was based on neuropsychological assessment with test scores falling 1.5 SD < mean on a single measure or 1.0 SD < mean on multiple measures per cognitive domain, according to aged-based norms. CC was based on informant report of difficulties in memory, orientation, judgment, social functioning, home-based activities, language, and recognition of others. MBI was based on the Neuropsychiatric Inventory (NPI), supplemented with informant interview. Participants were categorized as positive/negative for CC, MCI, or MBI only, or in combination; those negative on all three attributes served as the reference category. Separate Cox regression models examined CC-MCI-MBI status and time to all-cause dementia/AD or right censoring, covarying age, sex, education, and APOE ε4 status.

Result: One hundred fifty-six individuals developed dementia (118 AD). Compared to the reference category, MCI only [Hazard Ratio HR (95% CI) = 3.51 (1.49 - 8.22)], CC+MCI [HR (95%CI) = 5.24 (2.33 - 11.79), CC+MBI [HR (95%CI) = 5.29 (1.96 - 14.32)], MCI+MBI [HR (95%CI) = 4.31 (1.24 - 14.94), and CC+MCI+MBI [HR (95%CI) = 17.11 (7.58 - 38.65)] were associated with increased risk of dementia whereas MBI only or CC only was not. For AD, results were similar, except that MCI+MBI was not associated with increased risk (p = .165).

Conclusion: The presence of MCI with or without cognitive complaint or in combination with MBI predicted future AD or all-cause dementia. However, MBI was predictive only in combination with cognitive complaint/MCI. These results emphasize the importance of conducting both cognitive and behavioral assessments to buttress reports of cognitive concerns.

Download full-text PDF

Source
http://dx.doi.org/10.1002/alz.086971DOI Listing

Publication Analysis

Top Keywords

[hr 95%ci
16
cognitive complaint
8
mci mbi
8
all-cause dementia
8
reference category
8
associated increased
8
increased risk
8
dementia mbi
8
cognitive
7
mbi
7

Similar Publications

The neutrophil-to-lymphocyte ratio (NLR) may predict outcomes in end-stage liver disease, but its value after transjugular intrahepatic portosystemic shunt (TIPS) is unclear. This study explored the link between NLR and long-term outcomes in decompensated cirrhosis patients post-TIPS. We retrospectively analyzed 184 patients treated between January 2016 and December 2021, noting demographic data, lab results, and follow-up outcomes, including liver transplantation or death.

View Article and Find Full Text PDF

Background: Glucagon-like peptide-1 receptor agonist (GLP-1RA) treatment reduces cardiovascular events in type 2 diabetes. Yet, the impact of GLP-1RA treatment before ST-segment elevation myocardial infarction (STEMI) on long-term prognosis in patients with type 2 diabetes remains unclear. In patients with STEMI and type 2 diabetes, we aimed to investigate the association between long-term prognosis and GLP-1RA treatment before STEMI.

View Article and Find Full Text PDF

Background: Immune checkpoint inhibitors (ICIs) are recommended to treat patients with deficient mismatch repair/microsatellite instability high (dMMR/MSI-H) metastatic colorectal cancer (mCRC). Pivotal trials have fixed a maximum ICI duration of 2 years, without a compelling rationale. A shorter treatment duration has the potential to improve patients' quality of life and reduce both toxicity and cost without compromising efficacy.

View Article and Find Full Text PDF

Objective: Secondary sclerosing cholangitis (SSC) represents a disease with a poor prognosis increasingly diagnosed in clinical settings. Notably, SSC in critically ill patients (SSC-CIP) is the most frequent cause. Variables associated with worse prognosis remain unclear.

View Article and Find Full Text PDF

Prognostic Value of Response Evaluation Using PSMA PET/CT in Patients with Metastatic Prostate Cancer (RECIP 1.0): A Systematic Review and Meta-analysis.

Acad Radiol

January 2025

University Medical Imaging Toronto, Joint Department of Medical Imaging, University Health Network-Sinai Health System -Women's College Hospital, University of Toronto, Toronto, ON, Canada (S.A.M., P.V.H., U.M., A.B.D.). Electronic address:

Rationale And Objectives: Recently, the Response Evaluation Using PSMA PET/CT in Patients with Metastatic Castration-Resistant Prostate Cancer (RECIP 1.0) was proposed to better evaluate treatment response in prostate cancer patients using PET/CT with prostate-specific membrane antigen (PSMA) than more traditional approaches like metabolic PET evaluation response criteria in solid tumor (PERCIST 1.0).

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!